A study was conducted to investigate gastrointestinal motility in mice and the ability of cannabichromene to affect this motility. CBC is one of the major phytocannabinoids found within the Cannabis plant and is unique amongst the major cannabinoids as it activates the transient receptor potential ankyrin-1 (TRPA1) receptor within the endocannabinoid system. CBC also inhibits endocannabinoid inactivation while poorly binding with the CB1 and CB2 receptors in the brain.

The Italian led study induced inflammation in the small intestine of mice through the use of croton oil. Liquid chromatography-mass spectrometry was used to measure endocannabinoid, oleoylethanolamide, and palmitoylethanolamide levels. The cannabinoid and TRPA1 receptors in the mice were looked at by quantitative RT-PCR. Gastrointestinal motility factors such as gastrointestinal transit, whole gut transit, and colonic propulsion were studied in vivo.

The results of this study showed several key interactions of CBC on gastrointestinal motility. CBC did alter mRNA expression of TRPA 1 receptors ex vivo but did not change endocannabinoid levels. CBC normalized inflammation and the croton-oil induced hypermotility in vivo, suggesting that CBC may reduce hypermobility independently of the compounds ability to bind with cannabinoid receptors or TRPA1 receptors.

While CBC does appear to normalize in vivo intestinal motility, it does not seem to slow the rate of transit. CBC also displays an inhibitory effect without directly binding to receptors in the endocannabinoid system, resulting in clinical interest that needs further study but shows promise and potential in gastrointestinal dysmotility and other inflammatory diseases.


  1. Izzo, AA, et al. Inhibitory effect of cannabichromeme, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Br J Pharmacol. June 2012. Journal Impact Factor = 6.81. Times Cited = 22